These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
266 related items for PubMed ID: 30664998
1. The impact of external innovation on new drug approvals: A retrospective analysis. Liu X, Thomas CE, Felder CC. Int J Pharm; 2019 May 30; 563():273-281. PubMed ID: 30664998 [Abstract] [Full Text] [Related]
5. 2020 in review: FDA approvals of new medicines. Kinch MS, Kraft Z, Schwartz T. Drug Discov Today; 2021 Dec 30; 26(12):2794-2799. PubMed ID: 34252611 [Abstract] [Full Text] [Related]
7. Comparative analysis of FDA approvals by top 20 pharma companies (2014-2023). Schuhmacher A, Gassmann O, Hinder M, Hartl D. Drug Discov Today; 2024 Sep 30; 29(9):104128. PubMed ID: 39097219 [Abstract] [Full Text] [Related]
8. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules. G de la Torre B, Albericio F. Molecules; 2019 Feb 23; 24(4):. PubMed ID: 30813407 [Abstract] [Full Text] [Related]
9. The impact of incremental innovation in biopharmaceuticals: drug utilisation in original and supplemental indications. Berndt ER, Cockburn IM, Grépin KA. Pharmacoeconomics; 2006 Dec 23; 24 Suppl 2():69-86. PubMed ID: 23389490 [Abstract] [Full Text] [Related]
10. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Kaitin KI, DiMasi JA. Clin Pharmacol Ther; 2011 Feb 23; 89(2):183-8. PubMed ID: 21191382 [Abstract] [Full Text] [Related]
11. Lessons from 60 years of pharmaceutical innovation. Munos B. Nat Rev Drug Discov; 2009 Dec 23; 8(12):959-68. PubMed ID: 19949401 [Abstract] [Full Text] [Related]
12. An analysis of original research contributions toward FDA-approved drugs. Patridge EV, Gareiss PC, Kinch MS, Hoyer DW. Drug Discov Today; 2015 Oct 23; 20(10):1182-7. PubMed ID: 26113307 [Abstract] [Full Text] [Related]
14. Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan. Yamanaka T, Kano S. Expert Opin Ther Pat; 2016 Oct 23; 26(4):497-503. PubMed ID: 26881292 [Abstract] [Full Text] [Related]
16. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. Hao J, Rodriguez-Monguio R, Seoane-Vazquez E. PLoS One; 2015 Oct 23; 10(10):e0140708. PubMed ID: 26469277 [Abstract] [Full Text] [Related]
17. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. Lanthier M, Miller KL, Nardinelli C, Woodcock J. Health Aff (Millwood); 2013 Aug 23; 32(8):1433-9. PubMed ID: 23918488 [Abstract] [Full Text] [Related]
18. The origins of new drugs. Kneller R. Nat Biotechnol; 2005 May 23; 23(5):529-30. PubMed ID: 15877061 [No Abstract] [Full Text] [Related]
19. Recent drug approvals from the US FDA and EMEA: what the future holds. Pevarello P. Future Med Chem; 2009 Apr 23; 1(1):35-48. PubMed ID: 21426069 [Abstract] [Full Text] [Related]
20. [Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia]. Iida K, Yano T, Ikemori M, Ishida T, Nishimura N. Yakugaku Zasshi; 2021 Jun 01; 141(6):877-886. PubMed ID: 33642438 [Abstract] [Full Text] [Related] Page: [Next] [New Search]